Production (Stage)
CannaPharmaRX, Inc.
CPMD
$0.004
$0.000.00%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 4,278.29% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4,278.29% | -- | -- | -- | -- |
| Cost of Revenue | 358.10% | 5,396.04% | 5,025.69% | 2,705.21% | 2,705.21% |
| Gross Profit | -228.78% | -4,145.88% | -3,852.43% | -2,615.63% | -2,615.63% |
| SG&A Expenses | -55.12% | -53.38% | -100.42% | -91.40% | -79.85% |
| Depreciation & Amortization | -129.81% | -100.08% | -102.99% | -77.18% | -73.67% |
| Other Operating Expenses | -49.00% | -49.00% | -3.47% | -3.47% | -3.47% |
| Total Operating Expenses | 113.43% | 170.06% | -71.79% | -74.02% | -62.59% |
| Operating Income | -57.59% | -118.00% | 77.95% | 74.49% | 63.09% |
| Income Before Tax | 116.92% | -368.56% | 118.41% | 107.61% | 15.97% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 116.92% | -368.56% | 118.41% | 107.61% | 15.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 116.92% | -368.56% | 118.41% | 107.61% | 15.97% |
| EBIT | -57.59% | -118.00% | 77.95% | 74.49% | 63.09% |
| EBITDA | -86.65% | -169.31% | 82.40% | 82.35% | 68.68% |
| EPS Basic | 108.78% | -477.78% | 85.77% | 80.26% | 36.14% |
| Normalized Basic EPS | 109.74% | -184.85% | 3.87% | 5.23% | -52.57% |
| EPS Diluted | 108.78% | -477.78% | 85.77% | 80.26% | 36.14% |
| Normalized Diluted EPS | 109.74% | -184.85% | 3.87% | 5.23% | -52.57% |
| Average Basic Shares Outstanding | 103.05% | 87.39% | 77.86% | 52.88% | 32.04% |
| Average Diluted Shares Outstanding | 103.05% | 87.39% | 77.86% | 52.88% | 32.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |